The current pharma model aimed at blockbuster sales is a disservice to patients, according to Marc-Andre Gagnon, an economist at York University. In this issue of GEN, Gagnon reveals top pharmaceutical firms to be among the best brand-management firms with increasingly stealth advertising campaigns. He also acknowledges that said business model is quite profitable. What do you think about this dichotomy?